Wael A. Alghamdi, PharmD

Wael_AlghamdiContact Information

Email: wael@ufl.edu

Education

PharmD, MCPHS Unviersity – Manchester, NH
B.Pharm., King Khalid University – Abha, Saudi Arabia

Entry date into PTR PhD Program: Spring 2016
Curriculum Vitae

 

 

Research Interests

  • Tuberculosis/Infectious Diseases
  • Therapeutic drug monitoring
  • PK/PD Modeling

Professional Experience

  • Teaching Assistant – University of Florida, College of Pharmacy – January 2018 – present
  • Graduate Assistant – University of Florida, College of Pharmacy, IDPL – May 2016 – present
  • Teaching Assistant/Lecturer – King Khalid University, College of Pharmacy – December 2010 – present
  • ORISE fellow – FDA CDER OCP DPM – June 2018 – August 2018

Scholarship/Awards

  • Scholarship recipient – Saudi Arabian Cultural Mission, Ministry of Education
  • Steven Cohen Pharmaceutical Sciences Research Award
  • Golden Key International Honour Society
  • Phi Kappa Phi – All-discipline Honor Society
  • Rho Chi – Pharmacy Honor Society

Professional Memberships

  • American College of Clinical Pharmacy (ACCP) 
  • American Society for Clinical Pharmacology and Therapeutics (ASCPT) 
  • Infectious Diseases Society of America (IDSA) 
  • International Society of Pharmacometrics (ISoP)

Publications

  • Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. 2014. Vandetanib for the treatment of medullary thyroid carcinoma. Ann Pharmacother 48:387-94.
  • Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA. 2017. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol 10:1027-1036.
  • Singh S, McDonough CW, Gong Y, Alghamdi WA, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. 2018. Genome Wide Association Study Identifies the. J Am Heart Assoc 7.
  • Alghamdi WA, Al-Shaer MH, Peloquin CA. 2018. Protein Binding of First-Line Antituberculous Drugs. Antimicrob Agents Chemother.
  • Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T. 2018. Perspectives for personalized therapy for patients with multidrugresistant tuberculosis. J Intern Med.

Abstracts/Presentations

  • Alghamdi W, Barbakadze K, Horita Y, Kipiani M, Kempker R, Peloquin C. Pharmacokinetics of Bedaquiline and Delamanid in Patients with MDR-TB. 10th edition of the International Workshop on Pharmacology of Tuberculosis Drugs, Abstract 17; Atlanta, GA; October 15, 2017.
  • Alsultan A, Neely M, Alghamdi W, Alshaer M, Heysell S, Kempker R, Mpagama S, Kipiani M, Chongolo A, Houpt E, An G, Peloquin C. Population Pharmacokinetics of Cycloserine. 10th edition of the International Workshop on Pharmacology of Tuberculosis Drugs, Abstract 22; Atlanta, GA; October 15, 2017.
  • Singh S, Alghamdi W, Arwood MJ, Bargal SA, de Oliveira F, Dumeny L, Wen-Yi L, Mehanna M, Stockard B, Yang G, Fredette N, Shahin M, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Gong Y, McDonough CW, Cooper-DeHoff RM, Johnson JA. A Genome Wide Association Study to Identify Pharmacogenomic Variants Associated with Chlorthalidone Induced Glucose Change in African Americans. American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics 2017; 101:S9. (PT-019)